Audit: QRS - Dihexa for Cognitive Enhancement

Audit conducted on 10/30/2026 19:01 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 97
Passed 88
Failed 0
N/A 9
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Lede, protocol, time-to-effect, tiers, gates, markers, cadence and qualitative items each trace to ER passages (Conclusion, Therapeutic Protocol, Practical Considerations, Monitoring, Key Interactions).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Hedges kept: “No established human dose”, “not safety-adjusted”, “Common practice”, “the human time course for dihexa is unknown”, “central theoretical concern”, “largely unknown”.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening or softening found; dose and route cells carry the ER’s caveats in their sub lines.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications come from “Populations who should avoid Dihexa”, interactions from the documented/theoretical lists, risks from Potential Risks.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, NCT IDs or citations; named agents (fosgonimeton, MoCA, Semax, drug names) appear in the ER for the same facts.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Same cautious, evidence-skeptical register as the ER.
2.2 The tone of the QRS is expert, accessible, objective, and data-driven 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses the reader directly — it presents evidence, not guidance 🟢 No second-person address; “track change from own baseline” (line 654) is the ER’s verbatim target text.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms (eosinophilia, EGFR, Renin–angiotensin, Neurotrophic, ALT/AST) are part of ER labels carried verbatim.
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.10 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.11 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Lede frames use “for sharper memory”, notes no direct human testing and that the only human trial was in Alzheimer’s disease.
2.13 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” wording.
2.14 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 Routes given as “oral”, “injectable”, “injected”, “topical”.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed labels unchanged (diff against template).
3.2 Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name 🟢 All present; marker_# and qualitative_item_# expanded to numbered names per 14.2/15.2.
3.3 Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well 🟢 Diff shows changes only inside data-qrs-var spans, display:none attributes on spans, and workflow metadata fields.

4. Formatting

# Description Result Comments
4.1 An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. 🟢 Empty tiers (benefits High/Medium; risks High/Medium/Speculative) and time_3 are hidden.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 “Animal-derived estimate”, “Competing approaches”, “Single or split dosing” and the gate labels are verbatim ER bold labels.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Example lists trimmed with ER wording kept.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢  
4.5 The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. 🟢 Glosses dropped, example lists trimmed, no trailing dash clauses or repetitions.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2-14.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration is quoted; it contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.10.25.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 2026-1030-1837.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name 🟢 Opus.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model 🟢 Opus 5.5.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 10/30/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢  
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 “an unapproved research chemical derived from a blood-pressure hormone and used for sharper memory”.
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.3 [at_a_glance] is no longer than 70 words 🟢 70 words (script count).
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All five ER populations present.
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “(hereditary papillary renal carcinoma)” kept.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Not empty; ER names populations.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found 🟢 Cholinesterase inhibitors, the only documented item.
9.3 [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label 🟢 All seven theoretical items present.
9.4 The ER placeholder “None identified” is never an item: it means that group is empty 🟢  
9.5 Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause 🟢  
9.6 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.7 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Every item keeps at least one ER example.
9.8 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation.
9.9 If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. N/A Theoretical group not empty.
9.10 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Not empty.
9.11 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. N/A Section not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Therapeutic Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from that section 🟢 Dose (with no-established-dose caveat), route, and dosing frequency.
10.3 If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER gives more than three aspects.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Both ER aspects (rat memory, 8 days; fosgonimeton brain waves, 9 days) used.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Memory effect first, surrogate brain-wave change second.
11.3 If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. 🟢 time_3 spans empty and hidden.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER provides time-to-effect data.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 High and Medium hidden.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 All six Low risks listed by heading.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 High, Medium and Speculative hidden.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
14.2 All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names 🟢 Four table markers plus home blood pressure from the Baseline paragraph.
14.3 [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” 🟢 Targets match ER; blood pressure “Not specified in the ER”.
14.4 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. 🟢  
14.5 If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template N/A ER names biomarkers.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
15.2 All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … 🟢 All seven ER qualitative markers.
15.3 If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template N/A ER names qualitative markers.

Issues 10/30/2026 19:01

Pass rate 100.00%. No issues found.

Issues 10/30/2026 18:57

  1. 2.14 — Lay route-of-administration phrasing: Protocol action_2_sub (line 467) reads “oral, skin-applied and injected regimens”; “skin-applied” is lay phrasing where the formal term “topical” is required.

Fixes 10/30/2026 18:57

  1. 2.14 — Lay route-of-administration phrasing: Changed “skin-applied” to “topical” in Protocol action_2_sub (“oral, topical and injected regimens”).

Issues 10/30/2026 18:54

  1. 1.1 — Non-ER route wording: Protocol action_2_sub (line 467) reads “oral, topical and injected regimens”, but the ER Competing approaches bullet (ER line 280) says “oral, skin-applied and injected regimens”; “topical” is not ER wording.

Fixes 10/30/2026 18:54

  1. 1.1 — Non-ER route wording: Replaced “topical” with the ER’s “skin-applied” in Protocol action_2_sub, now “oral, skin-applied and injected regimens circulate without published sources”.

Issues 10/30/2026 18:51

  1. 2.14 — Lay route phrasing “skin-applied”: Line 467 (action_2_sub) reads “oral, skin-applied and injected regimens”; “skin-applied” is consumer-grade route-of-administration wording where the formal term is “topical”.

Fixes 10/30/2026 18:51

  1. 2.14 — Lay route phrasing replaced: Changed “oral, skin-applied and injected regimens” to “oral, topical and injected regimens” in action_2_sub (line 467).

Issues 10/30/2026 18:46

  1. 1.3 — Oral regimen implied sourced: Protocol action_2_sub (line 467) reads “topical and injected regimens circulate without published sources”, while the ER says “oral, skin-applied and injected regimens” circulate without published sources; omitting oral beside the value “Oral” implies a sourced oral regimen.

Fixes 10/30/2026 18:46

  1. 1.3 — Oral regimen implied sourced: Changed action_2_sub from “topical and injected regimens circulate without published sources” to “oral, skin-applied and injected regimens circulate without published sources”, matching the ER’s Competing approaches bullet.

Issues 10/30/2026 18:43

  1. 2.14 — Lay route phrasing: Protocol action_2_sub (line 467) reads “skin-applied and injected regimens”; “skin-applied” is consumer-grade wording for a route of administration in the document’s own voice.
  2. 9.7 — Example list dropped: The anticholinergic theoretical item (line 572) omits the ER’s “and bladder drugs (oxybutynin)” (ER line 245), dropping that parenthetical example list entirely.

Fixes 10/30/2026 18:43

  1. 2.14 — Lay route phrasing replaced: Changed action_2_sub “skin-applied and injected regimens” to “topical and injected regimens”.
  2. 9.7 — Example list restored: Restored “and bladder drugs (oxybutynin)” to the anticholinergic theoretical interaction item, per the ER bullet.

Issues 10/30/2026 18:39

  1. 2.7 — Jargon “prodrug” in sub: time_2_sub (line 506) reads “Altered in people given the injected prodrug fosgonimeton”; “prodrug” is pharmacology jargon outside any ER label, where a plain phrase such as the lede’s “injectable relative” would do.

Fixes 10/30/2026 18:39

  1. 2.7 — Jargon “prodrug” removed: Changed time_2_sub from “Altered in people given the injected prodrug fosgonimeton” to “Altered in people injected with fosgonimeton, a related drug the body converts into dihexa”.